Skip to main content

Table 1 Baseline characteristics of study patients

From: Epidemiology and cost of herpes zoster and postherpetic neuralgia among patients treated in primary care centres in the valencian community of Spain

Variable n = 130
   Age, years, median (range) 63.5 (19-94)
   Female gender, n (%) 83 (63.8)
Area of residence  
   Urban, n (%) 41 (31.5)
   Semiurban, n (%) 39 (30)
   Rural, n (%) 50 (38.5)
Predisposing clinical conditions† 60 (46.2)
   Immunosuppressant* use, n (%) 3 (2.3)
   Malignancy, n (%) 12 (9.2)
   HIV, n (%) 0
   Transplant, n (%) 1 (0.8)
   Chronic disease*, n (%) 39 (30)
   Trauma/burns/radiotherapy, n (%) 3 (2.3)
   Other** 6 (4.6)
   Not reflected in clinical history, n (%) 2 (1.5)
Complications†, n (%) 31 (23.8)
   Ocular, n (%) 11 (8.5)
   Bacterial superinfection, n (%) 7 (5.4)
   Dysgeusia, n (%) 4 (3.1)
   Hypoacusia, vertigo, tinnitus, n (%) 2 (1.5)
   Dissemination, n (%) 2 (1.5)
   Involvement of other organs, n (%) 1 (0.8)
   Other‡, n (%) 12 (9.2)
Use of antiviral agents, n (%) 119 (91.5)
Time elapsed from symptom onset to diagnosis, days (SD) 6.3 (5.8)
  1. SD: Standard deviation.
  2. HIV: Human immunodeficiency virus.
  3. * Administration of oral or systemic corticosteroids or chemotherapy treatment.
  4. † Each patient may have more than one baseline clinical condition/complication.
  5. * Chronic disease was defined as diabetes mellitus, chronic obstructive pulmonary disease, moderate or severe asthma, rheumatoid arthritis, chronic liver disease, chronic kidney disease, congenital heart disease, and systemic lupus erythematosus.
  6. ** Other risk factors refer to multisystem atrophy, major depression, postsurgical stress, influenza, and polysubstance abuse.
  7. ‡ Other complications refer to lymphadenopathy, activity limitation, fungal infection in the herpes zoster area, allergic reactions to treatment, weight loss, anorexia, vomiting, and diarrhea.
\